...
机译:miR-520g和miR-520h通过抑制ape1克服多发性骨髓瘤中的Bortezomib抗性
Zhengzhou Univ Henan Key Lab Hematol Henan Prov Peoples Hosp Dept Hematol Peoples Hosp;
Zhengzhou Univ Henan Key Lab Hematol Henan Prov Peoples Hosp Dept Hematol Peoples Hosp;
Zhengzhou Univ Henan Key Lab Hematol Henan Prov Peoples Hosp Dept Hematol Peoples Hosp;
Zhengzhou Univ Henan Key Lab Hematol Henan Prov Peoples Hosp Dept Hematol Peoples Hosp;
Zhengzhou Univ Henan Key Lab Hematol Henan Prov Peoples Hosp Dept Hematol Peoples Hosp;
Zhengzhou Univ Henan Key Lab Hematol Henan Prov Peoples Hosp Dept Hematol Peoples Hosp;
Zhengzhou Univ Affiliated Hosp 1 Dept Neurosurg Zhengzhou Henan Peoples R China;
DNA repair; homologous recombination; multiple myeloma; APE1; cell viability; bortezomib resistance;
机译:miR-520g和miR-520h通过抑制ape1克服多发性骨髓瘤中的Bortezomib抗性
机译:通过抑制多种骨髓瘤中的NF-κB信号通路来抑制脱氢素酶USP7克服了硼齐佐米的电阻
机译:发现肽硼酸盐衍生物作为组蛋白脱乙酰酶和蛋白酶体双抑制剂,用于克服多发性骨髓瘤的硼齐佐米抗性
机译:Bortezomib抗性多发性骨髓瘤的初步大规模定量蛋白质组学分析
机译:Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物,最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
机译:miR-520g和miR-520h通过抑制ape1克服多发性骨髓瘤中的Bortezomib抗性
机译:HIV蛋白酶抑制剂奈非那韦的治疗可触发未折叠的蛋白质反应,并可能与硼替佐米合用克服多发性骨髓瘤的蛋白酶体抑制剂耐药性:I期试验(SAKK 65/08)。